By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Portola Pharmaceuticals, Inc. 

270 East Grand Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-246-7000 Fax: 650-246-7376


Portola Pharmaceuticals, Inc. was founded in 2003 and is headquartered in South San Francisco, CA. We completed an initial public offering in May 2013 and are traded on the Nasdaq Stock Market under the symbol PTLA. We have approximately 80 employees. At Portola, our goal is to build an enduring biopharmaceutical company with compounds from our own research efforts that advance the care of patients in the areas of thrombosis (blood clots), other hematologic (blood) disorders and inflammation. Our development-stage portfolio includes three 100 percent-owned clinical-stage assets; betrixaban and andexanet alfa (PRT4445), which address significant unmet medical needs in the areas of thrombosis; and PRT2070, an orally available kinase inhibitor with unique pharmacologic properties that targets hematologic cancers.

Key Statistics

Ownership: Private

Web Site: Portola Pharmaceuticals, Inc.

Start Up

Company News
Portola Pharmaceuticals, Inc. Announces Dr. Robert Califf Retires From The Board Of Directors To Accept Position As Deputy Commissioner For Medical Products And Tobacco At The FDA 1/26/2015 11:02:50 AM
Portola Pharmaceuticals, Inc. Initiates Phase 4 Study To Support Accelerated Approval Of Andexanet Alfa -- Its Breakthrough-Designated Factor Xa Inhibitor Antidote 1/12/2015 6:52:13 AM
Portola Pharmaceuticals, Inc. Announces Phase 3 ANNEXA-R Study Of Andexanet Alfa And Factor Xa Inhibitor XARELTO® (Rivaroxaban) Met Primary Endpoint With High Statistical Significance 1/9/2015 7:41:44 AM
Portola Pharmaceuticals, Inc. Announces Webcast Of Corporate Presentation On January 12, 2015 1/6/2015 11:04:35 AM
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company (BMY) And Pfizer (PFE) Announce Statistically Significant Results From The First Part Of The Phase 3 ANNEXA(TM)-A Studies Of Investigational Andexanet Alfa With Eliquis (Apixaban) 11/17/2014 10:39:26 AM
Portola Pharmaceuticals, Inc. Reports Third Quarter Financial Results And Provides Corporate Update 11/11/2014 7:57:22 AM
Portola Pharmaceuticals, Inc. To Present At The Credit Suisse 2014 Healthcare Conference 11/6/2014 1:07:06 PM
Portola Pharmaceuticals, Inc. Announces Upcoming Presentations At The American Society of Hematology 2014 Annual Meeting 11/6/2014 10:44:12 AM
Portola Pharmaceuticals, Inc. To Announce Third Quarter 2014 Financial Results And Host Conference Call On Monday, November 10, 2014 11/3/2014 8:50:39 AM
Portola Pharmaceuticals, Inc. Announces Commercial Supply Agreement For Andexanet Alfa With Lonza Inc. 10/17/2014 7:17:33 AM